Novel esophageal capsule not ready for population screening for Barrett’s Esophagus
A novel esophageal capsule was not seen as ready for population screening for Barrett’s Esophagus, according to results form a pilot study.
“We assessed the diagnostic accuracy of a novel third generation capsule with an improved frame rate of 35 frames per second for the detection of BE in a pilot study,” Abhiram Duvvuri, MD, from the department of gastroenterology at Kansas City VA Medical Center, and colleagues wrote.
“Studies integrating artificial intelligence into improved quality novel esophageal capsule should be performed for BE screening,” they added.
Duvvuri and colleagues performed a blinded prospective pilot study of 20 patients with Barrett’s Esophagus who presented for endoscopic surveillance at a tertiary medical center. Patients received PilCam, a novel esophageal capsule (UGI, Medtronic) with an ingestion protocol. Then, patients underwent high definition upper endoscopy. Examiners, who were blinded to endoscopy results, interpreted capsule endoscopy findings and then compared endoscopic findings. Patients reported on their experience via a subjective questionnaire provided by the researchers.
Investigators reported a mean BE length of 3.5 cm. The novel esophageal capsule detected BE in 75% of patients when images were compared with endoscopy.
“Novel capsule detected BE in 82% patients when the BE length was [ at least 2 cm or more],” the investigators wrote.
According to researchers, mean esophageal transit time was 0.59 seconds. All patients reported the novel capsule was more convenient compared with upper endoscopy.